Hepatitis E vaccine [1]

New England Journal of Medicine

Volumn 356, Issue 23, 2007, Pages 2421-2422

  Basu, Sanjay ^a   Lurie, Peter ^b  

^a YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b Public Citizen Health Research Group   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

HEPATITIS VACCINE; RECOMBINANT VACCINE; BACTERIAL POLYSACCHARIDE; TYPHOID PARATYPHOID VACCINE; UNCLASSIFIED DRUG; VI POLYSACCHARIDE VACCINE, TYPHOID;

CLINICAL TRIAL; COMMUNITY; ETHICS; HEPATITIS E; HUMAN; INFORMED CONSENT; LETTER; NEPAL; PRIORITY JOURNAL; PROFIT; RISK ASSESSMENT; SOLDIER; UNITED STATES; HEPATITIS E VIRUS; HUMAN EXPERIMENT; NOTE;

HEPATITIS E; HEPATITIS E VIRUS; HUMAN EXPERIMENTATION; HUMANS; INFORMED CONSENT; MILITARY PERSONNEL; NEPAL; POLYSACCHARIDES, BACTERIAL; TYPHOID-PARATYPHOID VACCINES; VIRAL HEPATITIS VACCINES;

EID: 34250023510     PISSN: 00284793     EISSN: 15334406     Source Type: Journal    
DOI: 10.1056/NEJMc070884     Document Type: Letter

References (4)

1. Shrestha MP, Scott RM, Joshi DM, et al. Safety and efficacy of a recombinant hepatitis E vaccine. N Engl J Med 2007;356:895-903.
2. Stevenson P. Nepal calls the shots in hepatitis E virus vaccine trial. Lancet 2000;355:1623.
3. Bankowski Z, Levine RJ, eds. International ethical guidelines for biomedical research involving human subjects. Geneva: Council for the International Organization of Medical Sciences, 1993.
4. Jack A. GSK is criticized for army drug test. Financial Times. February 28, 2006.